Nordic Nanovector ASA - Results for Fourth Quarter and Full Year 2016 - Seite 2

Finally, as part of its strategy to broaden and diversify its pipeline, the company entered collaboration agreements with LegoChem and Heidelberg Pharma to explore potential of ADCs with non-radionuclide payloads for the treatment of leukaemias.

Luigi Costa, CEO of Nordic Nanovector, comments: "The company has made excellent progress during 2016 reaching significant milestones across the business and generating important momentum going into 2017. In particular, we anticipate the completion of the Lymrit 37-01 study with Betalutin® and the selection of a dosing regimen to take into the pivotal Phase 2 trial later in the year. Also, the recent financing is enabling the company to pursue multiple opportunities to capture more value across the NHL space and potentially beyond into other haematological cancers. We are looking forward to an exciting year ahead."

Operational Highlights Q4 2016

• Lymrit 37-01 trial advancing with a higher dosing regimen for Betalutin® in Arm 4
o Recruitment and treatment into Arm 4 on-track for a timely SRC evaluation and selection of dosing regimen for pivotal Phase 2 PARADIGME trial

• Results presented at ASH 2016 continue to highlight Betalutin®'s promising clinical profile
o Significant anti-tumour activity observed in monotherapy: ORR of 62%, CR 38% in Arm 1 patients receiving 15MBq/kg; consistent for 16 patients treated in Arm 1/Phase 2 (ORR 69%, CR 38%)
o Durable responses observed: median duration of response of 20.7 months for patients in Arm 1
o Well tolerated with predictable and manageable safety profile

• Further progress on R&D pipeline
o Entered into R&D collaborations with LegoChem Biosciences and Heidelberg Pharma to explore potential of ADCs with non-radionuclide payloads for the treatment of leukaemias

• New members join Executive Management Team and Board of Directors
o Dr Lisa Rojkjaer, MD, joined as Chief Medical Officer
o Dr Joanna Horobin, MD, elected as Non-executive Director

• New funds raised enable expanded and extended development strategy for novel targeted therapeutics
o Successful private placement raised NOK 499 million in gross proceeds (December 2016)

Post Period Events

• Decision to initiate clinical programmes targeting 2nd and 1st line FL in 2017 supported by preclinical data
o Results presented at ASH 2016 show synergistic anti-tumour effect of Betalutin® in combination with rituximab